SCHEDULE 13G: KH Feelux Co., Ltd Discloses 15.4% Stake in Liminatus Pharma, Inc.

KH Feelux Co., Ltd has disclosed a significant 15.4% beneficial ownership stake in Liminatus Pharma, Inc., holding 4,000,000 shares of common stock.

Summary

• KH Feelux Co., Ltd, a company based in the Republic of Korea, has filed a Schedule 13G disclosing beneficial ownership of 4,000,000 shares of common stock in Liminatus Pharma, Inc.
• This ownership represents 15.4% of Liminatus Pharma, Inc.'s common stock, based on 26,014,633 shares outstanding as reported in the Issuer's Registration Statement on Form S-1 filed on June 24, 2025.
• KH Feelux Co., Ltd holds sole voting power and sole dispositive power over all 4,000,000 shares.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing the control of Liminatus Pharma, Inc.

Sentiment

Score: 7

Explanation: The disclosure of a significant 15.4% stake by an institutional investor is generally a positive signal, indicating confidence in the company. The certification that the stake is not for control purposes also reduces potential concerns about activist pressure.

Positives

• A significant institutional investor, KH Feelux Co., Ltd, has taken a substantial 15.4% stake in Liminatus Pharma, Inc., potentially signaling confidence in the company's future prospects.
• The investor holds sole voting and dispositive power over 4,000,000 shares, indicating a clear and direct interest in the investment.

Risks

• The filing explicitly states that the shares were not acquired for the purpose of changing or influencing the control of the issuer, mitigating the immediate risk of a hostile takeover or activist campaign from this specific shareholder.

Future Outlook

Not applicable, as this filing is a disclosure of current ownership, not forward-looking guidance or projections.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing indicates a significant investment by a foreign entity, KH Feelux Co., Ltd, into a U.S. pharmaceutical company, Liminatus Pharma, Inc. Such cross-border investments can reflect global interest in specific sectors or companies, potentially driven by strategic partnerships, market access, or technological advancements within the pharmaceutical industry.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional shareholder could be viewed positively, potentially increasing investor confidence and liquidity. It also identifies a major holder whose future actions (e.g., buying more, selling) could influence the stock.

Key Dates

Keywords

Liminatus Pharma, KH Feelux, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing, pharmaceutical, biotech, equity stake